Expert Review of Vaccines最新文献

Controlling the COVID-19 pandemic through vaccination: a perspective from Indonesia. 通过疫苗接种控制COVID-19大流行：来自印度尼西亚的视角。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-01-15 DOI: 10.1080/14760584.2025.2451883

Rano K Sinuraya, Auliya A Suwantika, Maarten J Postma

引用次数: 0

Dilemma in prevention of pertussis infection among infants under six months in China.

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-01-28 DOI: 10.1080/14760584.2025.2459745

Xiang Sun

{"title":"Dilemma in prevention of pertussis infection among infants under six months in China.","authors":"Xiang Sun","doi":"10.1080/14760584.2025.2459745","DOIUrl":"10.1080/14760584.2025.2459745","url":null,"abstract":"Introduction: Pertussis poses a significant threat to infants under six months due to their immature immune systems, limited maternal antibody protection, and constraints in the vaccination schedule. Despite vaccination efforts, this group remains highly susceptible to severe complications. Addressing these challenges is crucial for improving the health outcomes of infants in China.Areas covered: This review examines the primary challenges in preventing pertussis infections among infants under six months in China, focusing on factors such as underdeveloped immune system and inadequate maternal antibody protection. It analyzes limitations in current vaccination strategies and the impact of socio-cultural factors, healthcare resource distribution, and surveillance inadequacies. A comprehensive literature search was conducted to identify potential solutions, including enhancing maternal immunization, adjusting early vaccination strategies, increasing vaccine coverage, and developing new vaccines. The review synthesizes current research findings and data to provide a detailed overview of these issues.Expert opinion: Infants under six months are particularly vulnerable to pertussis. Early and effective prevention strategies, such as enhanced maternal immunization and adjusted vaccination schedules, are needed. Increasing vaccine coverage and developing safer, more immunogenic vaccines are essential. Policymakers should prioritize these measures to reduce pertussis incidence and complications among infants in China.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"138-145"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Readiness assessment for cervical cancer elimination and prevention of human papillomavirus (HPV)-related cancers in Europe - are we winning the RACE? 欧洲消除宫颈癌和预防人乳头瘤病毒（hpv）相关癌症的准备情况评估——我们是否赢得了竞赛？

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2024-12-15 DOI: 10.1080/14760584.2024.2438759

Eugenia Karamousouli, Ugne Sabale, Stefano Valente, Fanut Morosan, Maria Heuser, Olivia Dodd, Danielle Riley, Louise Heron, Giovanna Elisa Calabrò, Theodoros Agorastos, Paul Sevelda, Zoárd Tibor Krasznai, Shay Nahum, Rune Horby

{"title":"Readiness assessment for cervical cancer elimination and prevention of human papillomavirus (HPV)-related cancers in Europe - are we winning the RACE?","authors":"Eugenia Karamousouli, Ugne Sabale, Stefano Valente, Fanut Morosan, Maria Heuser, Olivia Dodd, Danielle Riley, Louise Heron, Giovanna Elisa Calabrò, Theodoros Agorastos, Paul Sevelda, Zoárd Tibor Krasznai, Shay Nahum, Rune Horby","doi":"10.1080/14760584.2024.2438759","DOIUrl":"10.1080/14760584.2024.2438759","url":null,"abstract":"Introduction: To address the cervical cancer burden globally, the World Health Organization and European Union released strategies to facilitate HPV-related cancers prevention, including cervical cancer elimination. This research assessed European country level readiness to achieve cervical cancer elimination by adhering to such strategies.Areas covered: Readiness for cervical cancer elimination was assessed across a range of guiding questions relevant to three defined key domains: vaccination, screening, and treatment, each with two sub-domains focusing on decision making and implementation efforts. Publicly available data sources were used to inform the scoring across domains, to tier countries into either high, moderate-high, moderate-low, and low readiness archetypes.Key parameters identified associated with the high readiness archetype were high vaccination coverage rates (>70%), availability of gender neutral and catch-up vaccination, school-based vaccination availability, organized screening programs, use of HPV DNA primary screening tests, and data surveillance.Expert opinion: Our analysis highlights significant variability in decision making and implementation of vaccination, screening, and treatment programmes across Europe. Country scores expose the need for a multifaceted approach to achieve cervical cancer elimination in Europe, encompassing solid decision making commitments, implementation of these commitments, and the ability to collect, surveil, and apply the data use accurately.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"11-26"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142817315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sustained immunogenicity of bivalent protein COVID-19 vaccine SCTV01C against antigen matched and mismatched variants. 二价蛋白COVID-19疫苗SCTV01C对抗原匹配和不匹配变体的持续免疫原性

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-01-27 DOI: 10.1080/14760584.2025.2456231

Guiqiang Wang, Kexin Zhao, Xiuli Zhao, Yimin Cui, Peng He, Tianzuo Zhang, Yanchao Wang, Rui Shi, Yanhua Li, Qian Wang, Yanping Ren, Zhisong Chen, Xuedan Zhao, Zekang Xie, Yufei Liang, Qingyun Tian, Jing Pan, Chao Zhang, Ying Han, Yuyang Dai, Siyang Ni, Yun Zhang, Xinjie Yang, Yongpan Fu, Dongfang Liu, Jing Li, Miaomiao Zhang, Zhongyu Hu, Liangzhi Xie

{"title":"Sustained immunogenicity of bivalent protein COVID-19 vaccine SCTV01C against antigen matched and mismatched variants.","authors":"Guiqiang Wang, Kexin Zhao, Xiuli Zhao, Yimin Cui, Peng He, Tianzuo Zhang, Yanchao Wang, Rui Shi, Yanhua Li, Qian Wang, Yanping Ren, Zhisong Chen, Xuedan Zhao, Zekang Xie, Yufei Liang, Qingyun Tian, Jing Pan, Chao Zhang, Ying Han, Yuyang Dai, Siyang Ni, Yun Zhang, Xinjie Yang, Yongpan Fu, Dongfang Liu, Jing Li, Miaomiao Zhang, Zhongyu Hu, Liangzhi Xie","doi":"10.1080/14760584.2025.2456231","DOIUrl":"10.1080/14760584.2025.2456231","url":null,"abstract":"Background: The development of bivalent or multivalent vaccines offers a promising strategy for combating SARS-CoV-2 mutations.Research design and methods: In this phase 2 trial, conducted from 1 December 2021, to 25 July 2023, 392 unvaccinated adults aged ≥18 years were randomized to receive a primary series of two doses and a booster dose of SCTV01C, a bivalent protein SARS-CoV-2 vaccine.Results: Geometric mean titers (GMTs) of neutralizing antibodies (nAb) against live Alpha, Beta, Delta, and Omicron showed 85.4-, 100.0-, 32.1-, and 9.8-fold increase from baseline on 28 days, and 49.4-, 55.3-, 5.7-fold increase against live Alpha, Beta, and Omicron on 90 days after primary series. At Day 28 and Day 90 following the booster dose, GMTs of nAb against Beta, BA.2 and BA.5 variants showed 12.1- and 8.8-, 13.8- and 7.1-, 18.7-, and 11.9-fold of increase from baseline, respectively. Reactogenicity was generally mild, with one adverse event of special interest (AESI) and 9 ≥Grade 3 treatment-related adverse events (TRAEs); all recovered within 3 days.Conclusions: SCTV01C, when administered as both a primary series and a booster vaccination, exhibited encouraging sustained immunogenicity against both antigen-matched and antigen-mismatched variants, with no significant safety concerns.Clinical trial registration: www.clinicaltrials.gov identifier is NCT05148091.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"128-137"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Towards an HCV vaccine: an overview of the immunization strategies for eliciting an effective B-cell response. 迈向丙型肝炎疫苗：引发有效b细胞反应的免疫策略概述。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-01-28 DOI: 10.1080/14760584.2025.2452955

Gabriel L Costa, Giuseppe A Sautto

{"title":"Towards an HCV vaccine: an overview of the immunization strategies for eliciting an effective B-cell response.","authors":"Gabriel L Costa, Giuseppe A Sautto","doi":"10.1080/14760584.2025.2452955","DOIUrl":"10.1080/14760584.2025.2452955","url":null,"abstract":"Introduction: Fifty-eight million people worldwide are chronically infected with hepatitis C virus (HCV) and are at risk of developing cirrhosis and hepatocellular carcinoma (HCC). Direct-acting antivirals are highly effective; however, they are burdened by high costs and the unchanged risk of HCC and reinfection, making prophylactic countermeasures an urgent medical need. HCV high genetic diversity is one of the main obstacles to vaccine development. The protective role of the humoral response directed against the HCV E2 glycoprotein is well established, and broadly neutralizing antibodies play a crucial role in effective viral clearance.Areas covered: This review explores the HCV targets and the different vaccination approaches, encompassing different expression systems, antigen selection strategies, and delivery methods, focusing on those aimed at eliciting a broad and effective humoral response. Our search criteria included the keywords 'HCV,' 'Hepatitis C,' and 'vaccine' using publicly available databases. Following the screening, 54 papers were selected.Expert opinion: The investigation of novel vaccine platforms beyond traditional approaches is necessary. While progress has been made in this direction, continued investigations on the HCV virology, immunology, and vaccinology are essential to surmount associated obstacles, heling in the development of an HCV vaccine that can benefit the global public health.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"96-120"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143003056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Knowledge, attitudes, and perceptions towards pneumococcal vaccines among adults in the United States. 美国成年人对肺炎球菌疫苗的了解、态度和看法。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2024-12-19 DOI: 10.1080/14760584.2024.2441250

Salini Mohanty, Jui-Hua Tsai, Ning Ning, Ana Martinez, Rishi P Verma, Bianca Chun, Kelly D Johnson, Nicole Cossrow, M Doyinsola Bailey, Thomas Weiss, Elmira Flem, Jordana K Schmier

{"title":"Knowledge, attitudes, and perceptions towards pneumococcal vaccines among adults in the United States.","authors":"Salini Mohanty, Jui-Hua Tsai, Ning Ning, Ana Martinez, Rishi P Verma, Bianca Chun, Kelly D Johnson, Nicole Cossrow, M Doyinsola Bailey, Thomas Weiss, Elmira Flem, Jordana K Schmier","doi":"10.1080/14760584.2024.2441250","DOIUrl":"10.1080/14760584.2024.2441250","url":null,"abstract":"Objectives: The attitudes and perceptions of healthcare consumers (HCCs) are increasingly becoming more relevant in decision-making with healthcare providers and incorporated into healthcare decision-making by national immunization technical advisory groups and health technology assessment agencies. With newer pneumococcal vaccine options available, HCCs' attitudes and perceptions play a key role in gauging potential acceptance. The objective of this study was to assess HCCs' knowledge, attitudes, and perceptions toward pneumococcal vaccines for adults.Methods: Between March and May 2024, eligible U.S. adult HCCs were invited to participate in an online survey focusing on experiences and attitudes toward vaccines.Results: Among 141 participating HCCs, average age was 53.1 years. The majority of participants were male (51.1%) and 64.5% identified as White. Most HCCs received at least one vaccine in the past year (81.6%). HCCs most often received vaccines at medical offices and pharmacies. HCCs supported lowering the age-based pneumococcal vaccine recommendation to all adults 50 years and older and were willing to receive a supplemental pneumococcal vaccine dose following completion of the recommended series for additional protection.Conclusions: These findings indicate that new adult pneumococcal vaccines would be accepted and valued by HCCs if recommended by HCPs.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"45-52"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142828179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Modeling the potential public health and economic impact of different COVID-19 vaccination strategies with an adapted vaccine in the Kingdom of Saudi Arabia. 利用沙特阿拉伯王国的适应疫苗对不同COVID-19疫苗接种策略的潜在公共卫生和经济影响进行建模。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2024-12-17 DOI: 10.1080/14760584.2024.2438757

Nadine Al Akoury, Julia Spinardi, Hammam Haridy, Mostafa Moussa, Mohammed Attia Elshabrawi, Carlos Fernando Mendoza, Jingyan Yang, Josie Dodd, Moe H Kyaw, Benjamin Yarnoff

{"title":"Modeling the potential public health and economic impact of different COVID-19 vaccination strategies with an adapted vaccine in the Kingdom of Saudi Arabia.","authors":"Nadine Al Akoury, Julia Spinardi, Hammam Haridy, Mostafa Moussa, Mohammed Attia Elshabrawi, Carlos Fernando Mendoza, Jingyan Yang, Josie Dodd, Moe H Kyaw, Benjamin Yarnoff","doi":"10.1080/14760584.2024.2438757","DOIUrl":"10.1080/14760584.2024.2438757","url":null,"abstract":"Background: The dynamic evolution of the virus causing COVID-19 necessitates the development of adapted vaccines to protect against emerging variants.Research design and methods: A combined Markov-decision tree model estimated the outcomes of alternative vaccination strategies. The Saudi Arabian population was stratified into standard-risk and high-risk subpopulations, defined as either the population comprising individuals aged ≥ 65 years and individuals with at least one comorbidity. The model estimated the health and economic outcomes of vaccination based on age-specific inputs taken from published sources and national surveillance data.Results: The vaccination strategy targeting the elderly and high-risk subpopulation (was estimated to prevent 156,694 cases 12,800 hospitalizations, and 2,919 deaths and result in cost savings of SAR 1,239 million in direct costs and SAR 4,145 million in indirect costs. These gains increased with the vaccination strategies additionally targeting other subpopulations. Compared to the base case (aged ≥65 and those at high-risk), expanding vaccination coverage to 75% of the standard-risk population prevented more cases (323%), hospitalizations (154%), and deaths (60%) and increased the direct (232%) and indirect (270%) cost savings.Conclusions: The adoption of broad vaccination strategies using a vaccine adapted to the dominant variant in circulation would yield substantial benefits in Saudi Arabia.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"27-36"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trends in adolescent and adult vaccination in pharmacy and medical settings in the United States, 2018-2024: a database study. 2018-2024 年美国药房和医疗机构中青少年和成人疫苗接种趋势：一项数据库研究。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2024-12-22 DOI: 10.1080/14760584.2024.2441255

Yi Zheng, Dong Wang, Ya-Ting Chen, Kunal Saxena, Goran Bencina, Amanda L Eiden

{"title":"Trends in adolescent and adult vaccination in pharmacy and medical settings in the United States, 2018-2024: a database study.","authors":"Yi Zheng, Dong Wang, Ya-Ting Chen, Kunal Saxena, Goran Bencina, Amanda L Eiden","doi":"10.1080/14760584.2024.2441255","DOIUrl":"10.1080/14760584.2024.2441255","url":null,"abstract":"Background: Pharmacies can increase access to vaccines. This study aimed to describe trends in the proportion of adolescent and adult vaccinations administered in pharmacies in the United States from 2018 to 2024.Research design and methods: This was a retrospective cross-sectional analysis of medical and pharmacy claims from commercial health insurance enrollees. We recorded vaccinations received by enrollees ≥9 years of age from 2018 to 2023 (routine vaccines) or 2024 (seasonal vaccines). We calculated the annual proportion of vaccinations occurring in pharmacies and the accumulated percent change in vaccination rate during each year from 2020 onward compared to 2018-2019.Results: The proportion of routine vaccinations occurring in pharmacies was higher among adults than among adolescents. For most routine vaccines, this proportion increased during the study period. The lowest proportion was observed for adolescent human papillomavirus vaccination in 2018 (0.2%), and the highest for herpes zoster vaccination among adults ≥65 years of age in 2023 (88.6%). For all age groups, pharmacy-based vaccination was more common for seasonal influenza and SARS-CoV-2 vaccines than for all routine vaccines except herpes zoster.Conclusions: Pharmacy-based vaccination is increasingly common in the United States, particularly among adults and for seasonal vaccines, and can help increase the overall level of vaccine uptake.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"53-66"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142828180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Application of reverse cumulative distribution curve and scaled logit model in determining optimal immunogenic dose and prediction of protection of EV71 vaccines. 反向累积分布曲线和比例logit模型在EV71疫苗最佳免疫原剂量确定和保护预测中的应用。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2024-12-18 DOI: 10.1080/14760584.2024.2438760

Lairun Jin, Pengfei Jin, Xuefeng Zhang, Fengcai Zhu, Jingxin Li

{"title":"Application of reverse cumulative distribution curve and scaled logit model in determining optimal immunogenic dose and prediction of protection of EV71 vaccines.","authors":"Lairun Jin, Pengfei Jin, Xuefeng Zhang, Fengcai Zhu, Jingxin Li","doi":"10.1080/14760584.2024.2438760","DOIUrl":"10.1080/14760584.2024.2438760","url":null,"abstract":"Background: This study proposes the reverse cumulative distribution curve (RCDC) for optimal dose selection and a scaled logit model for estimating protection in EV71 vaccine development.Research design and methods: Data were from a phase 2 trial involving infants and young children randomized to receive either 640 U with or without adjuvant, 320 U with adjuvant, 160 U with adjuvant EV71 vaccines, or placebo. RCDCs were constructed using neutralizing antibody titers 28 days post-vaccination. Robustness of RCDC parameters was assessed via coefficient of variation for the area under the curve (AUC), the relative optimal point, median on the curve, and antibody titer of the point of maximum curvature, with geometric mean titer (GMT) as control. The scaled logit model estimated protection against EV71-associated disease for the selected optimal dose.Results: The AUC and relative optimal point demonstrated greater robustness than GMT. The 640 U with adjuvant dose had the highest AUC (0.64, 95% CI: 0.61-0.66), sum of coordinates of the relative optimal point (1.40, 95% CI: 1.34-1.43), and the highest estimated protection (93.36%, 95% CI: 79.91-97.86).Conclusions: AUC and relative optimal point of RCDC are effective for early vaccine dose screening, with protection estimated by the scaled logit model.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"37-44"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Economic evaluation of childhood pneumococcal conjugate vaccination programs in Qinghai and Hainan provinces, China. 中国青海省和海南省儿童肺炎球菌结合疫苗接种计划的经济评价。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2024-12-24 DOI: 10.1080/14760584.2024.2443223

Haonan Zhang, Chaofan Wang, Haijun Zhang, Brian Wahl, Maria Deloria Knoll, Xiaozhen Lai, Hai Fang

{"title":"Economic evaluation of childhood pneumococcal conjugate vaccination programs in Qinghai and Hainan provinces, China.","authors":"Haonan Zhang, Chaofan Wang, Haijun Zhang, Brian Wahl, Maria Deloria Knoll, Xiaozhen Lai, Hai Fang","doi":"10.1080/14760584.2024.2443223","DOIUrl":"10.1080/14760584.2024.2443223","url":null,"abstract":"Background: The burden of pneumococcal disease varies regionally in China, disproportionately affecting children in many provinces such as Qinghai and Hainan. Nevertheless, the absence of a pneumococcal conjugate vaccine (PCV) in the National Immunization Program (NIP) or local programs presents limited coverage. This study evaluated the health and economic impact of including PCV in immunization programs in Qinghai and Hainan.Research design and methods: A decision tree Markov model was constructed to simulate health outcomes and lifetime costs among children under different 13-valent PCV (PCV13) vaccination strategies compared to current practices, from societal and healthcare perspectives. Data on epidemiology, vaccine efficacy, cost, and utility were obtained from the literature and open databases. Sensitivity analyses were conducted to explore parameter uncertainty.Results: Including three-dose PCV13 in provincial programs at NIP coverage (98.91%) could avert 7100 episodes and 118 deaths in Qinghai, and 6200 episodes and 66 deaths in Hainan. It was cost-effective at the $68.2/dose in private market and cost-saving at the United Nations Children's Fund (UNICEF) recommended $25/dose for both provinces. Increasing coverage to 50% or 75% was also cost-effective. Sensitivity analyses confirmed the robustness of the results despite parameter uncertainty.Conclusions: Prioritizing PCV13 in immunization programs in Qinghai and Hainan could effectively reduce disease burden, improve population health, and promote health equity.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"67-80"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142834496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0